Report Information More information from: https ://www.wis eguyreports .com/reports /495878
Oropharyngeal Cancer - Pipeline Review, H1 2016 Report / Search Code: WGR495878
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Oropharyngeal Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Oropharyngeal Cancer - Pipeline Review, H1 2016’, provides an overview of the Oropharyngeal Cancer pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Oropharyngeal Cancer, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Oropharyngeal Cancer - The report reviews pipeline therapeutics for Oropharyngeal Cancer by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Oropharyngeal Cancer therapeutics and enlis ts all their major and minor projects - The report as s es s es Oropharyngeal Cancer therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Oropharyngeal Cancer Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Oropharyngeal Cancer - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics
- Devis e corrective meas ures for pipeline projects by unders tanding Oropharyngeal Cancer pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Oropharyngeal Cancer Overview 8 Therapeutics Development 9 Pipeline Products for Oropharyngeal Cancer - Overview 9 Pipeline Products for Oropharyngeal Cancer - Comparative Analys is 10 Oropharyngeal Cancer - Therapeutics under Development by Companies 11 Oropharyngeal Cancer - Therapeutics under Inves tigation by Univers ities /Ins titutes 12 Oropharyngeal Cancer - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Oropharyngeal Cancer - Products under Development by Companies 16 Oropharyngeal Cancer - Products under Inves tigation by Univers ities /Ins titutes 17 Oropharyngeal Cancer - Companies Involved in Therapeutics Development 18 Advaxis , Inc. 18 As traZ eneca Plc 19 Genticel S.A. 20 Kolltan Pharmaceuticals , Inc. 21 Merck & Co., Inc. 22 Novartis AG 23 PNP Therapeutics , Inc. 24 Synta Pharmaceuticals Corp. 25 VLPbio 26 Oropharyngeal Cancer - Therapeutics As s es s ment 27 As s es s ment by Monotherapy Products 27 As s es s ment by Target 28 As s es s ment by Mechanis m of Action 30 As s es s ment by Route of Adminis tration 32 As s es s ment by Molecule Type 34 Drug Profiles 36 alpelis ib - Drug Profile 36 Product Des cription 36 Mechanis m of Action 36 R& D Progres s 36 axalimogene filolis bac - Drug Profile 38 Product Des cription 38 Mechanis m of Action 38 R& D Progres s 38 Cellular Immunotherapy for HPV As s ociated Cancers - Drug Profile 43 Product Des cription 43 Mechanis m of Action 43 R& D Progres s 43 ganetes pib - Drug Profile 44 Product Des cription 44 Mechanis m of Action 44 R& D Progres s 44 gedeptin - Drug Profile 49 Product Des cription 49 Mechanis m of Action 49 R& D Progres s 49 GTL-001 - Drug Profile 50 Product Des cription 50 Mechanis m of Action 50 R& D Progres s 50 HNVax - Drug Profile 52 Product Des cription 52 Mechanis m of Action 52 R& D Progres s 52 KTN-3379 - Drug Profile 53 Product Des cription 53 Mechanis m of Action 53 R& D Progres s 53 LN-145 - Drug Profile 55
Product Des cription 55 Mechanis m of Action 55 R& D Progres s 55 nimotuzumab - Drug Profile 57 Product Des cription 57 Mechanis m of Action 57 R& D Progres s 57 olaparib - Drug Profile 61 Product Des cription 61 Mechanis m of Action 61 R& D Progres s 61 pembrolizumab - Drug Profile 65 Product Des cription 65 Mechanis m of Action 65 R& D Progres s 65 PGV-001 - Drug Profile 76 Product Des cription 76 Mechanis m of Action 76 R& D Progres s 76 TT-12 - Drug Profile 77 Product Des cription 77 Mechanis m of Action 77 R& D Progres s 77 Oropharyngeal Cancer - Recent Pipeline Updates 78 Oropharyngeal Cancer - Dormant Projects 131 Oropharyngeal Cancer - Product Development Miles tones 132 Featured News & Pres s Releas es 132 Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phas e 2 Study of AXAL Highlights Potential of the Company’s Lm Technology™ Platform 132 Sep 14, 2015: FDA Awards Grant for Phas e 2 Study of Axalimogene Filolis bac in HPVAs s ociated Head and Neck Cancer 133 Appendix 135 Methodology 135 Coverage 135 Secondary Res earch 135 Primary Res earch 135 Expert Panel Validation 135 Contact Us 135 Dis claimer 136 Lis t of Tables Number of Products under Development for Oropharyngeal Cancer, H1 2016 9 Number of Products under Development for Oropharyngeal Cancer - Comparative Analys is , H1 2016 10 Number of Products under Development by Companies , H1 2016 11 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 12 Comparative Analys is by Late Stage Development, H1 2016 13 Comparative Analys is by Clinical Stage Development, H1 2016 14 Comparative Analys is by Early Stage Development, H1 2016 15 Products under Development by Companies , H1 2016 16 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 17 Oropharyngeal Cancer - Pipeline by Advaxis , Inc., H1 2016 18 Oropharyngeal Cancer - Pipeline by As traZ eneca Plc, H1 2016 19 Oropharyngeal Cancer - Pipeline by Genticel S.A., H1 2016 20 Oropharyngeal Cancer - Pipeline by Kolltan Pharmaceuticals , Inc., H1 2016 21 Oropharyngeal Cancer - Pipeline by Merck & Co., Inc., H1 2016 22 Oropharyngeal Cancer - Pipeline by Novartis AG, H1 2016 23 Oropharyngeal Cancer - Pipeline by PNP Therapeutics , Inc., H1 2016 24 Oropharyngeal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 25 Oropharyngeal Cancer - Pipeline by VLPbio, H1 2016 26 As s es s ment by Monotherapy Products , H1 2016 27 Number of Products by Stage and Target, H1 2016 29 Number of Products by Stage and Mechanis m of Action, H1 2016 31 Number of Products by Stage and Route of Adminis tration, H1 2016 33 Number of Products by Stage and Molecule Type, H1 2016 35 Oropharyngeal Cancer Therapeutics - Recent Pipeline Updates , H1 2016 78 Oropharyngeal Cancer - Dormant Projects , H1 2016 131 Lis t of Figures Number of Products under Development for Oropharyngeal Cancer, H1 2016 9 Number of Products under Development for Oropharyngeal Cancer - Comparative Analys is , H1 2016 10 Number of Products under Development by Companies , H1 2016 11 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 12 Comparative Analys is by Clinical Stage Development, H1 2016 14 Comparative Analys is by Early Stage Products , H1 2016 15 As s es s ment by Monotherapy Products , H1 2016 27 Number of Products by Top 10 Targets , H1 2016 28 Number of Products by Stage and Top 10 Targets , H1 2016 28 Number of Products by Mechanis m of Actions , H1 2016 30
Number Number Number Number Number
of of of of of
Products Products Products Products Products
by by by by by
Stage and Top 10 Mechanis m of Actions , H1 2016 30 Routes of Adminis tration, H1 2016 32 Stage and Routes of Adminis tration, H1 2016 32 Molecule Types , H1 2016 34 Stage and Molecule Types , H1 2016 34
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349